{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T08:47:35Z","timestamp":1775638055431,"version":"3.50.1"},"reference-count":22,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2013,11,14]],"date-time":"2013-11-14T00:00:00Z","timestamp":1384387200000},"content-version":"vor","delay-in-days":13,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Metabolism Res"],"published-print":{"date-parts":[[2013,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aims<\/jats:title><jats:p>This study aimed to assess the risk of non\u2010fatal cardiovascular events among patients with type 2 diabetes mellitus (T2DM) who are taking metformin, glimepiride or glyburide.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>Using the National Health Insurance Research database in Taiwan, this retrospective cohort study identified 1159 patients with newly diagnosed T2DM from 1998 to 2007, 30\u2009years and older and without a history of cardiovascular disease at baseline. Patients with cancer, liver cirrhosis or chronic kidney disease were excluded. On the basis of prescription, patients were grouped into three medication subcohorts: metformin (<jats:italic>N<\/jats:italic>\u2009=\u2009595), glimepiride (<jats:italic>N<\/jats:italic>\u2009=\u2009234) or glyburide (<jats:italic>N<\/jats:italic>\u2009=\u2009330) monotherapy for 100% of the follow\u2010up period without any oral anti\u2010diabetic agents added or changed, by the end of 2009. Incidence and hazard ratios of non\u2010fatal cardiovascular events including coronary artery disease, peripheral artery disease, stroke and heart failure among these three subcohorts were compared.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The overall incidence of non\u2010fatal cardiovascular events was the highest for patients taking glyburide (169.1 per 1000 person\u2010years), followed by for those taking glimepiride and metformin (95.2 and 49.1 per 1000 person\u2010years, respectively). Compared with the adjusted hazard ratio for patients taking glyburide, the adjusted hazard ratio for those taking glimepiride was 0.52 (95% CI 0.40\u20130.69) and for those taking metformin was 0.31 (95% CI 0.24\u20130.40).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>T2DM patients taking metformin and glimepiride are at lower risk of non\u2010fatal cardiovascular events than those taking glyburide. Copyright \u00a9 2013 John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/dmrr.2444","type":"journal-article","created":{"date-parts":[[2013,8,19]],"date-time":"2013-08-19T08:01:11Z","timestamp":1376899271000},"page":"673-679","source":"Crossref","is-referenced-by-count":12,"title":["Oral hypoglycaemic agents and the development of non\u2010fatal cardiovascular events in patients with type 2 diabetes mellitus"],"prefix":"10.1002","volume":"29","author":[{"given":"Yi\u2010Chih","family":"Hung","sequence":"first","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Internal Medicine China Medical University Hospital  Taichung 40447 Taiwan"},{"name":"Department of Internal Medicine China Medical University  Taichung 40447 Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Che\u2010Chen","family":"Lin","sequence":"additional","affiliation":[{"name":"Management Office for Health Data China Medical University Hospital  Taichung 40447 Taiwan"},{"name":"Department of Public Health China Medical University  Taichung 40447 Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tzu\u2010Yuan","family":"Wang","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Internal Medicine China Medical University Hospital  Taichung 40447 Taiwan"},{"name":"School of Chinese Medicine China Medical University  Taichung 40447 Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Man\u2010Ping","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Nursing, School of Health National Taichung University of Science and Technology  Taichung 40343 Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fung\u2010Chang","family":"Sung","sequence":"additional","affiliation":[{"name":"Management Office for Health Data China Medical University Hospital  Taichung 40447 Taiwan"},{"name":"Department of Public Health China Medical University  Taichung 40447 Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ching\u2010Chu","family":"Chen","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Internal Medicine China Medical University Hospital  Taichung 40447 Taiwan"},{"name":"School of Chinese Medicine China Medical University  Taichung 40447 Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,11,14]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.27.5.1047"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0808431"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)07037-8"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0802987"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0802743"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe0807625"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.25.12.2244"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-157-9-201211060-00003"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-0413"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-0017"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-0449"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehr077"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2012.01604.x"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.971"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.1031414"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00395-011-0216-6"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001204"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.168.19.2088"},{"key":"e_1_2_7_20_1","unstructured":"Canadian Agency for Drugs and Technologies in Health.Current utilization of second\u2010 and third\u2010line therapies in patients with type 2 diabetes. CADTH optimal therapy report2010;4:1\u201333."},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2011.01496.x"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1053\/euhj.1998.1242"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc06-1789"}],"container-title":["Diabetes\/Metabolism Research and Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fdmrr.2444","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/dmrr.2444","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T17:53:50Z","timestamp":1697651630000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/dmrr.2444"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":22,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["10.1002\/dmrr.2444"],"URL":"https:\/\/doi.org\/10.1002\/dmrr.2444","archive":["Portico"],"relation":{},"ISSN":["1520-7552","1520-7560"],"issn-type":[{"value":"1520-7552","type":"print"},{"value":"1520-7560","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11]]}}}